Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above
Clinical trial NCT05829356 · COMPLETED
Trial details
- NCT number
- NCT05829356
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-12
- Primary completion
- 2024-03-14
- Enrollment
- 159
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.